How lengthy does it take completely different nations/areas to approve new medicines? The US is the quickest and Europe is the slowest amongst chosen main pharmaceutical markets in response to a report by EFPIA.

Furthermore, whereas a majority (7 out of 10) of therapies within the US depend on expedited approval, in Europe lower than 1 in 10 are accredited through these pathways.

You may learn EFPIA’s full report and response to the EU pharmaceutical packet right here.